^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    daraxonrasib (RMC-6236)

    i
    Company:
    Revolution Medicines
    Drug class:
    RAS inhibitor
    Related drugs:
    Apply
    Phase 3 Study of RMC-6236 in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RASolute 302) (NCT06625320)
    Phase 3
    Revolution Medicines, Inc.
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    10/16/2024
    Primary completion :
    06/01/2026
    Completion :
    12/01/2027
    RAS
    |
    RAS mutation
    |
    gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • leucovorin calcium • daraxonrasib (RMC-6236)
    Study of RMC-6291 in Combination With RMC-6236 in Participants With Advanced KRAS G12C Mutant Solid Tumors (NCT06128551)
    Phase 1
    Revolution Medicines, Inc.
    Recruiting
    Last update posted :
    06/17/2024
    Initiation :
    11/14/2023
    Primary completion :
    11/30/2026
    Completion :
    11/30/2026
    KRAS
    |
    daraxonrasib (RMC-6236) • elironrasib (RMC-6291)
    Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS (NCT05379985)
    Phase 1
    Revolution Medicines, Inc.
    Recruiting
    Last update posted :
    02/23/2024
    Initiation :
    05/31/2022
    Primary completion :
    06/01/2024
    Completion :
    12/01/2025
    KRAS
    |
    KRAS mutation • RAS mutation • KRAS G12
    |
    daraxonrasib (RMC-6236)